New diabetes drug shows promise in 12-Week trial
NCT ID NCT00998881
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tested a new diabetes medicine called MP-513 (Teneligliptin) in 203 Japanese adults with type 2 diabetes. The goal was to see if the drug safely lowers blood sugar levels over 12 weeks compared to a placebo. Participants had to be between 20 and 75 years old, manage their diabetes with diet and exercise, and have an HbA1c between 6.5% and 10.0%. The main measure was the change in HbA1c from the start to week 12.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Sapporo, Hokkaido, Japan
Conditions
Explore the condition pages connected to this study.